RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000071.xml
PDF herunterladen
Semin Neurol 2023; 43(01): 004-016
DOI: 10.1055/s-0043-1764140
DOI: 10.1055/s-0043-1764140
Review Article
Global Epidemiology of Movement Disorders: Rare or Underdiagnosed?
Abstract
In this manuscript, we review the epidemiology of movement disorders including Parkinson's disease (PD), atypical parkinsonism, essential tremor, dystonia, functional movement disorders, tic disorders, chorea, and ataxias. We emphasize age-, sex-, and geography-based incidence and prevalence, as well as notable trends including the rising incidence and prevalence of PD. Given the growing global interest in refining clinical diagnostic skills in recognizing movement disorders, we highlight some key epidemiological findings that may be of interest to clinicians and health systems tasked with diagnosing and managing the health of patients with movement disorders.
Keywords
epidemiology - parkinsonism - dystonia - essential tremor - atypical parkinsonism - tic disorders - ataxia - chorea - Huntington's diseasePublikationsverlauf
Artikel online veröffentlicht:
09. März 2023
© 2023. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Fahn S. Classification of movement disorders. Mov Disord 2011; 26 (06) 947-957
- 2 Bach JP, Ziegler U, Deuschl G, Dodel R, Doblhammer-Reiter G. Projected numbers of people with movement disorders in the years 2030 and 2050. Mov Disord 2011; 26 (12) 2286-2290
- 3 Fereshtehnejad SM, Rahmani A, Shafieesabet M. et al. Prevalence and associated comorbidities of restless legs syndrome (RLS): data from a large population-based door-to-door survey on 19176 adults in Tehran, Iran. PLoS One 2017; 12 (02) e0172593
- 4 Fereshtehnejad SM, Shafieesabet M, Rahmani A. et al. A novel 6-item screening questionnaire for Parkinsonism: validation and comparison between different instruments. Neuroepidemiology 2014; 43 (3-4): 178-193
- 5 Wei Z, Xiaoyuan N, Shengwei G, Zhizong H, Jiyuan L, Yang L. Evaluation of a screening questionnaire for Parkinson's disease in a Chinese population. J Clin Neurosci 2014; 21 (02) 278-281
- 6 Sernadela P, González-Castro L, Carta C. et al. Linked registries: connecting rare diseases patient registries through a semantic web layer. BioMed Res Int 2017; 2017: 8327980
- 7 Sugawara M, Watanabe S, Toyoshima I. Prevalence of dystonia in Akita Prefecture in Northern Japan. Mov Disord 2006; 21 (07) 1047-1049
- 8 Sugawara N, Yasui-Furukori N, Umeda T. et al. Clock drawing performance in a community-dwelling population: Normative data for Japanese subjects. Aging Ment Health 2010; 14 (05) 587-592
- 9 Lolekha P, Phanthumchinda K, Bhidayasiri R. Prevalence and risk factors of Parkinson's disease in retired Thai traditional boxers. Mov Disord 2010; 25 (12) 1895-1901
- 10 Lolekha P, Tangkanakul C, Saengchatri T, Kulkeartprasert P. The Six-item Clock-Drawing Scoring System: a rapid screening for cognitive impairment in Parkinson's disease. Psychogeriatrics 2021; 21 (01) 24-31
- 11 Jagota P, Srivanitchapoom P, Petchrutchatachart S. et al. Validation of the Thai Version of the Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale. J Mov Disord 2022; 15 (02) 151-155
- 12 World Health O.. Parkinson Disease: A Public Health Approach: Technical Brief. World Health Organization; 2022. Accessed February 10, 2023 at: https://apps.who.int/iris/handle/10665/355973
- 13
GBD 2016 Parkinson's Disease Collaborators.
Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic
analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018; 17 (11)
939-953
MissingFormLabel
- 14 Dorsey ER, Bloem BR. The Parkinson pandemic-a call to action. JAMA Neurol 2018; 75 (01) 9-10
- 15 Twelves D, Perkins KSM, Counsell C. Systematic review of incidence studies of Parkinson's disease. Mov Disord 2003; 18 (01) 19-31
- 16 Hirsch L, Jette N, Frolkis A, Steeves T, Pringsheim T. The incidence of Parkinson's disease: a systematic review and meta-analysis. Neuroepidemiology 2016; 46 (04) 292-300
- 17 Willis AW, Roberts E, Beck JC. et al; Parkinson's Foundation P4 Group. Incidence of Parkinson disease in North America. NPJ Parkinsons Dis 2022; 8 (01) 170
- 18 Allen L. Are we facing a noncommunicable disease pandemic?. J Epidemiol Glob Health 2017; 7 (01) 5-9
- 19 Zhong QQ, Zhu F. Trends in prevalence cases and disability-adjusted life-years of Parkinson's disease: findings from the Global Burden of Disease Study 2019. Neuroepidemiology 2022; 56 (04) 261-270
- 20 Rossi A, Berger K, Chen H, Leslie D, Mailman RB, Huang X. Projection of the prevalence of Parkinson's disease in the coming decades: revisited. Mov Disord 2018; 33 (01) 156-159
- 21 Marras C, Beck JC, Bower JH. et al; Parkinson's Foundation P4 Group. Prevalence of Parkinson's disease across North America. NPJ Parkinsons Dis 2018; 4: 21
- 22 Kissani N, Liqali L, Hakimi K. et al. Why does Africa have the lowest number of neurologists and how to cover the gap?. J Neurol Sci 2022; 434: 120119
- 23 Blauwendraat C, Nalls MA, Singleton AB. The genetic architecture of Parkinson's disease. Lancet Neurol 2020; 19 (02) 170-178
- 24 Nalls MA, Blauwendraat C, Vallerga CL. et al; 23andMe Research Team, System Genomics of Parkinson's Disease Consortium, International Parkinson's Disease Genomics Consortium. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurol 2019; 18 (12) 1091-1102
- 25 Lesage S, Brice A. Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet 2009; 18 (R1): R48-R59
- 26 Kim CY, Alcalay RN. Genetic forms of Parkinson's disease. Semin Neurol 2017; 37 (02) 135-146
- 27 Cook L, Schulze J, Verbrugge J. et al; ClinGen Parkinson's Disease Gene Curation Expert Panel and the MDS Task Force for Recommendations for Genetic Testing in Parkinson's Disease, Clinical Genome Resource (ClinGen) Parkinson's Disease Gene Curation Expert Panel Authors, Movement Society Disorder (MDS) Task Force on Recommendations for Clinical Genetic Testing in Parkinson's Disease Authors. The commercial genetic testing landscape for Parkinson's disease. Parkinsonism Relat Disord 2021; 92: 107-111
- 28 Alcalay RN, Mirelman A, Saunders-Pullman R. et al. Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations. Mov Disord 2013; 28 (14) 1966-1971
- 29 Healy DG, Falchi M, O'Sullivan SS. et al; International LRRK2 Consortium. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008; 7 (07) 583-590
- 30 Kasten M, Klein C. The many faces of alpha-synuclein mutations. Mov Disord 2013; 28 (06) 697-701
- 31 Ando M, Funayama M, Li Y. et al. VPS35 mutation in Japanese patients with typical Parkinson's disease. Mov Disord 2012; 27 (11) 1413-1417
- 32 Zimprich A, Benet-Pagès A, Struhal W. et al. A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet 2011; 89 (01) 168-175
- 33 Bonifati V, Rohé CF, Breedveld GJ. et al; Italian Parkinson Genetics Network. Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. Neurology 2005; 65 (01) 87-95
- 34 Ibáñez P, Lesage S, Lohmann E. et al; French Parkinson's Disease Genetics Study Group. Mutational analysis of the PINK1 gene in early-onset parkinsonism in Europe and North Africa. Brain 2006; 129 (Pt 3): 686-694
- 35 Kilarski LL, Pearson JP, Newsway V. et al. Systematic review and UK-based study of PARK2 (parkin), PINK1, PARK7 (DJ-1) and LRRK2 in early-onset Parkinson's disease. Mov Disord 2012; 27 (12) 1522-1529
- 36 Rogaeva E, Johnson J, Lang AE. et al. Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease. Arch Neurol 2004; 61 (12) 1898-1904
- 37 Valente EM, Salvi S, Ialongo T. et al. PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann Neurol 2004; 56 (03) 336-341
- 38 Klein C, Djarmati A, Hedrich K. et al. PINK1, Parkin, and DJ-1 mutations in Italian patients with early-onset parkinsonism. Eur J Hum Genet 2005; 13 (09) 1086-1093
- 39 Bonifati V, Rizzu P, van Baren MJ. et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003; 299 (5604): 256-259
- 40 Riboldi GM, Di Fonzo AB. GBA, Gaucher disease, and Parkinson's disease: from genetic to clinic to new therapeutic approaches. Cells 2019; 8 (04) 364
- 41 Anheim M, Elbaz A, Lesage S. et al; French Parkinson Disease Genetic Group. Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers. Neurology 2012; 78 (06) 417-420
- 42 Balestrino R, Tunesi S, Tesei S, Lopiano L, Zecchinelli AL, Goldwurm S. Penetrance of glucocerebrosidase (GBA) mutations in Parkinson's disease: a kin cohort study. Mov Disord 2020; 35 (11) 2111-2114
- 43 Gao HM, Hong JS. Gene-environment interactions: key to unraveling the mystery of Parkinson's disease. Prog Neurobiol 2011; 94 (01) 1-19
- 44 Ball N, Teo WP, Chandra S, Chapman J. Parkinson's disease and the environment. Front Neurol 2019; 10: 218
- 45 Hernán MA, Takkouche B, Caamaño-Isorna F, Gestal-Otero JJ. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol 2002; 52 (03) 276-284
- 46 Checkoway H, Powers K, Smith-Weller T, Franklin GM, Longstreth Jr WT, Swanson PD. Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. Am J Epidemiol 2002; 155 (08) 732-738
- 47 Chen H, Huang X, Guo X. et al. Smoking duration, intensity, and risk of Parkinson disease. Neurology 2010; 74 (11) 878-884
- 48 World Health Organization. WHO Global Report on Trends in Prevalence of Tobacco Smoking 2000–2025. Published online 2018. Accessed February 10, 2023 at: https://www.who.int/publications/i/item/9789240039322
- 49 Ullah I, Zhao L, Hai Y. et al. “Metal elements and pesticides as risk factors for Parkinson's disease - a review”. Toxicol Rep 2021; 8: 607-616
- 50 Vlaar T, Kab S, Schwaab Y, Fréry N, Elbaz A, Moisan F. Association of Parkinson's disease with industry sectors: a French nationwide incidence study. Eur J Epidemiol 2018; 33 (11) 1101-1111
- 51 Cicero CE, Mostile G, Vasta R. et al. Metals and neurodegenerative diseases. A systematic review. Environ Res 2017; 159: 82-94
- 52 Lee PC, Raaschou-Nielsen O, Lill CM. et al. Gene-environment interactions linking air pollution and inflammation in Parkinson's disease. Environ Res 2016; 151: 713-720
- 53 Ritz BR, Paul KC, Bronstein JM. Of pesticides and men: a California story of genes and environment in Parkinson's disease. Curr Environ Health Rep 2016; 3 (01) 40-52
- 54 Jo S, Kim YJ, Park KW. et al. Association of NO2 and other air pollution exposures with the risk of Parkinson disease. JAMA Neurol 2021; 78 (07) 800-808
- 55 Gorell JM, Johnson CC, Rybicki BA. et al. Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease. Neurotoxicology 1999; 20 (2-3): 239-247
- 56 Wang A, Costello S, Cockburn M, Zhang X, Bronstein J, Ritz B. Parkinson's disease risk from ambient exposure to pesticides. Eur J Epidemiol 2011; 26 (07) 547-555
- 57 Kamel F, Tanner C, Umbach D. et al. Pesticide exposure and self-reported Parkinson's disease in the agricultural health study. Am J Epidemiol 2007; 165 (04) 364-374
- 58 Baltazar MT, Dinis-Oliveira RJ, de Lourdes Bastos M, Tsatsakis AM, Duarte JA, Carvalho F. Pesticides exposure as etiological factors of Parkinson's disease and other neurodegenerative diseases–a mechanistic approach. Toxicol Lett 2014; 230 (02) 85-103
- 59 Singh N, Lawana V, Luo J. et al. Organophosphate pesticide chlorpyrifos impairs STAT1 signaling to induce dopaminergic neurotoxicity: Implications for mitochondria mediated oxidative stress signaling events. Neurobiol Dis 2018; 117: 82-113
- 60 National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee to Review the Health Effects in Vietnam Veterans of Exposure to Herbicides (Eleventh Biennial Update). Veterans and Agent Orange: Update 11 (2018). Washington (DC): National Academies Press (US); ; November 15, 2018
- 61 Stellman JM, Stellman SD. Agent Orange during the Vietnam War: the lingering issue of its civilian and military health impact. Am J Public Health 2018; 108 (06) 726-728
- 62 Paul KC, Sinsheimer JS, Cockburn M, Bronstein JM, Bordelon Y, Ritz B. Organophosphate pesticides and PON1 L55M in Parkinson's disease progression. Environ Int 2017; 107: 75-81
- 63 Viscidi E, Litvan I, Dam T. et al. Clinical features of patients with progressive supranuclear palsy in an US insurance claims database. Front Neurol 2021; 12: 571800
- 64 Respondek G, Stamelou M, Kurz C. et al; Movement Disorder Society-endorsed PSP Study Group. The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord 2014; 29 (14) 1758-1766
- 65 Swallow DMA, Zheng CS, Counsell CE. Systematic review of prevalence studies of progressive supranuclear palsy and corticobasal syndrome. Mov Disord Clin Pract (Hoboken) 2022; 9 (05) 604-613
- 66 Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 1999; 354 (9192): 1771-1775
- 67 Bjornsdottir A, Gudmundsson G, Blondal H, Olafsson E. Incidence and prevalence of multiple system atrophy: a nationwide study in Iceland. J Neurol Neurosurg Psychiatry 2013; 84 (02) 136-140
- 68 Adler CH, Beach TG, Zhang N. et al. Clinical diagnostic accuracy of early/advanced parkinson disease: an updated clinicopathologic study. Neurol Clin Pract 2021; 11 (04) e414-e421
- 69 Koga S, Dickson DW. Recent advances in neuropathology, biomarkers and therapeutic approach of multiple system atrophy. J Neurol Neurosurg Psychiatry 2018; 89 (02) 175-184
- 70 Koga S, Aoki N, Uitti RJ. et al. When DLB, PD, and PSP masquerade as MSA: an autopsy study of 134 patients. Neurology 2015; 85 (05) 404-412
- 71 Martin WRW, Miles M, Zhong Q. et al. Is levodopa response a valid indicator of Parkinson's disease?. Mov Disord 2021; 36 (04) 948-954
- 72
Bhatia KP,
Bain P,
Bajaj N.
et al;
Tremor Task Force of the International Parkinson and Movement Disorder Society.
Consensus Statement on the classification of tremors. from the task force on tremor
of the International Parkinson and Movement Disorder Society. Mov Disord 2018; 33
(01) 75-87
MissingFormLabel
- 73 Louis ED, McCreary M. How common is essential tremor? Update on the worldwide prevalence of essential tremor. Tremor Other Hyperkinet Mov (N Y) 2021; 11: 28
- 74 Louis ED, Ottman R. How many people in the USA have essential tremor? Deriving a population estimate based on epidemiological data. Tremor Other Hyperkinet Mov (N Y) 2014; 4: 259
- 75 Marras C, Armstrong MJ, Meaney CA. et al. Measuring mild cognitive impairment in patients with Parkinson's disease. Mov Disord 2013; 28 (05) 626-633
- 76 Benito-León J, Louis ED. Essential tremor: emerging views of a common disorder. Nat Clin Pract Neurol 2006; 2 (12) 666-678 , quiz 2p, 691
- 77 Putzke JD, Whaley NR, Baba Y, Wszolek ZK, Uitti RJ. Essential tremor: predictors of disease progression in a clinical cohort. J Neurol Neurosurg Psychiatry 2006; 77 (11) 1235-1237
- 78 Louis ED, Ferreira JJ. How common is the most common adult movement disorder? Update on the worldwide prevalence of essential tremor. Mov Disord 2010; 25 (05) 534-541
- 79 Dotchin CL, Walker RW. The prevalence of essential tremor in rural northern Tanzania. J Neurol Neurosurg Psychiatry 2008; 79 (10) 1107-1109
- 80 Okubadejo NU, Bankole IA, Ojo OO, Ojini FI, Danesi MA. Prevalence of essential tremor in urban Lagos, Nigeria: a door-to-door community-based study. BMC Neurol 2012; 12 (01) 110
- 81 Rautakorpi I, Takala J, Marttila RJ, Sievers K, Rinne UK. Essential tremor in a Finnish population. Acta Neurol Scand 1982; 66 (01) 58-67
- 82 Benito-León J, Bermejo-Pareja F, Morales JM, Vega S, Molina JA. Prevalence of essential tremor in three elderly populations of central Spain. Mov Disord 2003; 18 (04) 389-394
- 83 Louis ED, Dogu O. Does age of onset in essential tremor have a bimodal distribution? Data from a tertiary referral setting and a population-based study. Neuroepidemiology 2007; 29 (3–4): 208-212
- 84 Louis ED, Huey ED, Cosentino S. Features of “ET plus” correlate with age and tremor duration: “ET plus” may be a disease stage rather than a subtype of essential tremor. Parkinsonism Relat Disord 2021; 91: 42-47
- 85 Iglesias-Hernandez D, Delgado N, McGurn M, Huey ED, Cosentino S, Louis ED. “ET Plus”: instability of the diagnosis during prospective longitudinal follow-up of essential tremor cases. Front Neurol 2021; 12: 782694
- 86 Berry DS, Hernandez N, Clark LN, Louis ED. Lack of familial aggregation of the “Essential Tremor-Plus” phenotype in familial essential tremor. Neuroepidemiology 2022; 56 (05) 373-379
- 87 Grütz K, Klein C. Dystonia updates: definition, nomenclature, clinical classification, and etiology. J Neural Transm (Vienna) 2021; 128 (04) 395-404
- 88 Pana A, Saggu B. Dystonia. [Updated 2022 Sep 5]. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2022
- 89 Ebiol B, Yalcin G, Dressler E, Altenmuller E, Krauss J. Epidemiology of Dystonia, in Treatment of Dystonia. Cambridge: Cambridge University Press; 2018
- 90
Albanese A,
Bhatia K,
Bressman SB.
et al.
Phenomenology and classification of dystonia: a consensus update. Mov Disord 2013;
28 (07) 863-873
MissingFormLabel
- 91 Defazio G, Abbruzzese G, Livrea P, Berardelli A. Epidemiology of primary dystonia. Lancet Neurol 2004; 3 (11) 673-678
- 92 Steeves TD, Day L, Dykeman J, Jette N, Pringsheim T. The prevalence of primary dystonia: a systematic review and meta-analysis. Mov Disord 2012; 27 (14) 1789-1796
- 93 Medina A, Nilles C, Martino D, Pelletier C, Pringsheim T. The prevalence of idiopathic or inherited isolated dystonia: a systematic review and meta-analysis. Mov Disord Clin Pract (Hoboken) 2022; 9 (07) 860-868
- 94 Das SK, Banerjee TK, Biswas A. et al. Community survey of primary dystonia in the city of Kolkata, India. Mov Disord 2007; 22 (14) 2031-2036
- 95 Joensen P. High prevalence of primary focal dystonia in the Faroe Islands. Acta Neurol Scand 2016; 133 (01) 55-60
- 96 Saunders-Pullman R, Fuchs T, San Luciano M. et al. Heterogeneity in primary dystonia: lessons from THAP1, GNAL, and TOR1A in Amish-Mennonites. Mov Disord 2014; 29 (06) 812-818
- 97 UK10K Consortium, Deciphering Developmental Disorders Study, NIHR BioResource Rare Diseases Consortium. et al. Mutations in the histone methyltransferase gene KMT2B cause complex early-onset dystonia. Nat Genet 2017; 49 (02) 223-237
- 98 Zech M, Jech R, Boesch S. et al. Monogenic variants in dystonia: an exome-wide sequencing study. Lancet Neurol 2020; 19 (11) 908-918
- 99 Zech M, Boesch S, Maier EM. et al. Haploinsufficiency of KMT2B, encoding the lysine-specific histone methyltransferase 2B, results in early-onset generalized dystonia. Am J Hum Genet 2016; 99 (06) 1377-1387
- 100 Gorman KM, Meyer E, Kurian MA. Review of the phenotype of early-onset generalised progressive dystonia due to mutations in KMT2B. Eur J Paediatr Neurol 2018; 22 (02) 245-256
- 101 Lange LM, Junker J, Loens S. et al. Genotype-phenotype relations for isolated dystonia genes: MDSGene systematic review. Mov Disord 2021; 36 (05) 1086-1103
- 102 Gilmour GS, Lidstone SC, Lang AE. The diagnosis of functional movement disorder. Pract Neurol 2022; (March/April): 40-53
- 103 Bennett K, Diamond C, Hoeritzauer I. et al. A practical review of functional neurological disorder (FND) for the general physician. Clin Med (Lond) 2021; 21 (01) 28-36
- 104 Carson A, Hallett M, Stone J. Assessment of patients with functional neurologic disorders. Handb Clin Neurol 2016; 139: 169-188
- 105 Stone J, Carson A, Duncan R. et al. Who is referred to neurology clinics?–the diagnoses made in 3781 new patients. Clin Neurol Neurosurg 2010; 112 (09) 747-751
- 106 Carson AJ, Brown R, David AS. et al; UK-FNS. Functional (conversion) neurological symptoms: research since the millennium. J Neurol Neurosurg Psychiatry 2012; 83 (08) 842-850
- 107 Espay AJ, Aybek S, Carson A. et al. Current concepts in diagnosis and treatment of functional neurological disorders. JAMA Neurol 2018; 75 (09) 1132-1141
- 108 Bodde NM, Brooks JL, Baker GA, Boon PA, Hendriksen JG, Aldenkamp AP. Psychogenic non-epileptic seizures–diagnostic issues: a critical review. Clin Neurol Neurosurg 2009; 111 (01) 1-9
- 109 MacDuffie KE, Grubbs L, Best T. et al. Stigma and functional neurological disorder: a research agenda targeting the clinical encounter. CNS Spectr 2020; 3: 1-6
- 110 Lidstone SC, Costa-Parke M, Robinson EJ, Ercoli T, Stone J. FMD GAP Study Group. Functional movement disorder gender, age and phenotype study: a systematic review and individual patient meta-analysis of 4905 cases. J Neurol Neurosurg Psychiatry 2022; 93 (06) 609-616
- 111 Deka K, Chaudhury PK, Bora K, Kalita P. A study of clinical correlates and socio-demographic profile in conversion disorder. Indian J Psychiatry 2007; 49 (03) 205-207
- 112 Naidoo L, Bhigjee AI. The spectrum of functional neurological disorders: a retrospective analysis at a tertiary hospital in South Africa. S Afr J Psychiatr 2021; 27: 1607
- 113 Aybek S, Lidstone SC, Nielsen G. et al. What is the role of a specialist assessment clinic for FND? Lessons from three national referral centers. J Neuropsychiatry Clin Neurosci 2020; 32 (01) 79-84
- 114 Stephen CD, Fung V, Lungu CI, Espay AJ. Assessment of emergency department and inpatient use and costs in adult and pediatric functional neurological disorders. JAMA Neurol 2021; 78 (01) 88-101
- 115 Ueda K, Black KJ. A comprehensive review of tic disorders in children. J Clin Med 2021; 10 (11) 24479
- 116 Knight T, Steeves T, Day L, Lowerison M, Jette N, Pringsheim T. Prevalence of tic disorders: a systematic review and meta-analysis. Pediatr Neurol 2012; 47 (02) 77-90
- 117 Robakis D. How much do we know about adult-onset primary tics? prevalence, epidemiology, and clinical features. Tremor Other Hyperkinet Mov (N Y) 2017; 7: 441
- 118 Levine JLS, Szejko N, Bloch MH. Meta-analysis: adulthood prevalence of Tourette syndrome. Prog Neuropsychopharmacol Biol Psychiatry 2019; 95: 109675
- 119 Kumar A, Trescher W, Byler D. Tourette syndrome and comorbid neuropsychiatric conditions. Curr Dev Disord Rep 2016; 3 (04) 217-221
- 120 Jones K, Saylam E, Ramphul K. Tourette Syndrome And Other Tic Disorders. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2022
- 121 Snider LA, Seligman LD, Ketchen BR. et al. Tics and problem behaviors in schoolchildren: prevalence, characterization, and associations. Pediatrics 2002; 110 (2, Pt 1): 331-336
- 122 Cox JH, Nahar A, Termine C. et al. Social stigma and self-perception in adolescents with tourette syndrome. Adolesc Health Med Ther 2019; 10: 75-82
- 123 Wild EJ, Tabrizi SJ. The differential diagnosis of chorea. Pract Neurol 2007; 7 (06) 360-373
- 124 Bovenzi R, Conti M, Cerroni R. et al. Adult-onset sporadic chorea: real-world data from a single-centre retrospective study. Neurol Sci 2022; 43 (01) 387-392
- 125 McColgan P, Tabrizi SJ. Huntington's disease: a clinical review. Eur J Neurol 2018; 25 (01) 24-34
- 126 Medina A, Mahjoub Y, Shaver L, Pringsheim T. Prevalence and incidence of Huntington's disease: an updated systematic review and meta-analysis. Mov Disord 2022; 37 (12) 2327-2335
- 127 Squitieri F, Andrew SE, Goldberg YP. et al. DNA haplotype analysis of Huntington disease reveals clues to the origins and mechanisms of CAG expansion and reasons for geographic variations of prevalence. Hum Mol Genet 1994; 3 (12) 2103-2114
- 128 Warby SC, Montpetit A, Hayden AR. et al. CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup. Am J Hum Genet 2009; 84 (03) 351-366
- 129 Hayden MR, MacGregor JM, Beighton PH. The prevalence of Huntington's chorea in South Africa. S Afr Med J 1980; 58 (05) 193-196
- 130 Baine FK, Kay C, Ketelaar ME. et al. Huntington disease in the South African population occurs on diverse and ethnically distinct genetic haplotypes. Eur J Hum Genet 2013; 21 (10) 1120-1127
- 131 Badry R, Abdelhamed MA, Sayed MAM, ElHady AA, Mostafa M. Epidemiology of dystonia, chorea, and athetosis in Al Quseir City (Red Sea Governorate), Egypt. Egypt J Neurol Psychiat Neurosurg 2019; 55 (01) 58
- 132 al Rajeh S, Bademosi O, Ismail H. et al. A community survey of neurological disorders in Saudi Arabia: the Thugbah study. Neuroepidemiology 1993; 12 (03) 164-178
- 133 Demiroren K, Yavuz H, Cam L, Oran B, Karaaslan S, Demiroren S. Sydenham's chorea: a clinical follow-up of 65 patients. J Child Neurol 2007; 22 (05) 550-554
- 134 Ben Hamida M, Hamza F. Sydenham's chorea in Tunisia: a report on 65 cases (author's transl) [in French]. Ann Med Interne (Paris) 1979; 130 (6–7): 359-364
- 135 Tumas V, Caldas CT, Santos AC, Nobre A, Fernandes RMF. Sydenham's chorea: clinical observations from a Brazilian movement disorder clinic. Parkinsonism Relat Disord 2007; 13 (05) 276-283
- 136 Wenning GK, Geser F, Krismer F. et al; European Multiple System Atrophy Study Group. The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol 2013; 12 (03) 264-274
- 137 Yabe I, Soma H, Takei A, Fujiki N, Yanagihara T, Sasaki H. MSA-C is the predominant clinical phenotype of MSA in Japan: analysis of 142 patients with probable MSA. J Neurol Sci 2006; 249 (02) 115-121
- 138 Ruano L, Melo C, Silva MC, Coutinho P. The global epidemiology of hereditary ataxia and spastic paraplegia: a systematic review of prevalence studies. Neuroepidemiology 2014; 42 (03) 174-183
- 139 van de Warrenburg BPC, Sinke RJ, Verschuuren-Bemelmans CC. et al. Spinocerebellar ataxias in the Netherlands: prevalence and age at onset variance analysis. Neurology 2002; 58 (05) 702-708
- 140 Hersheson J, Haworth A, Houlden H. The inherited ataxias: genetic heterogeneity, mutation databases, and future directions in research and clinical diagnostics. Hum Mutat 2012; 33 (09) 1324-1332
- 141 Jacquemont ML, Sanlaville D, Redon R. et al. Array-based comparative genomic hybridisation identifies high frequency of cryptic chromosomal rearrangements in patients with syndromic autism spectrum disorders. J Med Genet 2006; 43 (11) 843-849
- 142 Brussino A, Gellera C, Saluto A. et al. FMR1 gene premutation is a frequent genetic cause of late-onset sporadic cerebellar ataxia. Neurology 2005; 64 (01) 145-147
- 143 Van Esch H, Bauters M, Ignatius J. et al. Duplication of the MECP2 region is a frequent cause of severe mental retardation and progressive neurological symptoms in males. Am J Hum Genet 2005; 77 (03) 442-453
- 144 Macpherson J, Waghorn A, Hammans S, Jacobs P. Observation of an excess of fragile-X premutations in a population of males referred with spinocerebellar ataxia. Hum Genet 2003; 112 (5-6): 619-620
- 145 Polo JM, Calleja J, Combarros O, Berciano J. Hereditary ataxias and paraplegias in Cantabria, Spain. An epidemiological and clinical study. Brain 1991; 114 (Pt 2): 855-866
- 146 Kirilenko NB, Fedotov VP, Baryshnikova NV, Dadali EL, Poliakov AV. Nozological spectrum of hereditary diseases of the nervous system in the cities of Volgograd and Volzhsky [in Russian]. Genetika 2004; 40 (09) 1262-1267
- 147 Vankan P. Prevalence gradients of Friedreich's ataxia and R1b haplotype in Europe co-localize, suggesting a common Palaeolithic origin in the Franco-Cantabrian ice age refuge. J Neurochem 2013; 126 (Suppl. 01) 11-20
- 148 McCoy TH, Castro VM, Cagan A, Roberson AM, Kohane IS, Perlis RH. Sentiment measured in hospital discharge notes is associated with readmission and mortality risk: an electronic health record study. PLoS One 2015; 10 (08) e0136341
- 149 Wenning GK, Colosimo C, Geser F, Poewe W. Multiple system atrophy. Lancet Neurol 2004; 3 (02) 93-103
- 150 Nath U, Ben-Shlomo Y, Thomson RG. et al. The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK. Brain 2001; 124 (Pt 7): 1438-1449
- 151 Osaki Y, Morita Y, Kuwahara T, Miyano I, Doi Y. Prevalence of Parkinson's disease and atypical parkinsonian syndromes in a rural Japanese district. Acta Neurol Scand 2011; 124 (03) 182-187
- 152 Vicente E, Ruiz de Sabando A, García F, Gastón I, Ardanaz E, Ramos-Arroyo MA. Validation of diagnostic codes and epidemiologic trends of Huntington disease: a population-based study in Navarre, Spain. Orphanet J Rare Dis 2021; 16 (01) 77
- 153 Kim HS, Lyoo CH, Lee PH. et al. Current status of Huntington's disease in Korea: a nationwide survey and national registry analysis. J Mov Disord 2015; 8 (01) 14-20
- 154 Adachi Y, Nakashima K. Population genetic study of Huntington's disease–prevalence and founder's effect in the San-in area, western Japan [in Japanese]. Jpn J Clin Med 1999; 57 (04) 900-904
- 155 Chen YY, Lai CH. Nationwide population-based epidemiologic study of Huntington's Disease in Taiwan. Neuroepidemiology 2010; 35 (04) 250-254
- 156 Scrimgeour EM. Huntington disease (chorea) in the middle East. Sultan Qaboos Univ Med J 2009; 9 (01) 16-23
- 157 Cubo E, Doumbe J, Mapoure Njankouo Y. et al. The burden of movement disorders in Cameroon: a rural and urban-based inpatient/outpatient study. Mov Disord Clin Pract (Hoboken) 2017; 4 (04) 568-573
- 158 Peterlin B, Kobal J, Teran N, Flisar D, Lovrecić L. Epidemiology of Huntington's disease in Slovenia. Acta Neurol Scand 2009; 119 (06) 371-375
- 159 Muroni A, Murru MR, Sechi M. et al. Prevalence of Huntington's disease in Southern Sardinia, Italy. Parkinsonism Relat Disord 2020; 80: 54-57
- 160 Evans SJ, Douglas I, Rawlins MD, Wexler NS, Tabrizi SJ, Smeeth L. Prevalence of adult Huntington's disease in the UK based on diagnoses recorded in general practice records. J Neurol Neurosurg Psychiatry 2013; 84 (10) 1156-1160
- 161 Gilling M, Budtz-Jørgensen E, Boonen SE. et al. The Danish HD Registry-a nationwide family registry of HD families in Denmark. Clin Genet 2017; 92 (03) 338-341
- 162 Ohlmeier C, Saum KU, Galetzka W, Beier D, Gothe H. Epidemiology and health care utilization of patients suffering from Huntington's disease in Germany: real world evidence based on German claims data. BMC Neurol 2019; 19 (01) 318
- 163 Exuzides A, Reddy SR, Chang E. et al. Epidemiology of Huntington's disease in the United States Medicare and Medicaid populations. Neuroepidemiology 2022; 56 (03) 192-200
- 164 Scahill L, Specht M, Page C. The prevalence of tic disorders and clinical characteristics in children. J Obsessive Compuls Relat Disord 2014; 3 (04) 294-400